GlassScriptPhysician profile
Deewan Deewan
NPI 1811292055
$3,322.74
in general payments reported to CMS, 2019-2025
23 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.04 · 2020: $216 · 2021: $419 · 2022: $518 · 2023: $563 · 2024: $778 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Education: $21.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.82 |
| Education | $21.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $518.61 | 2021-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $433.95 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $370.42 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $335.50 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $283.58 | 2019-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $242.90 | 2020-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $241.60 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $179.84 | 2023-2025 | |
| Travere Therapeutics, INC. | $127.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $96.87 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $94.90 | 2020-2024 | Veltassa |
| Glaxosmithkline, LLC. | $81.06 | 2021 | |
| Aurinia Pharma U.S., INC. | $69.96 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $50.10 | 2023-2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.60 | 2023-2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $31.87 | 2024 | Defencath |
| Alnylam Pharmaceuticals INC. | $27.55 | 2023 | Onpattro |
| Siemens Medical Solutions USA, INC. | $20.41 | 2022 | |
| Ani Pharmaceuticals, INC. | $17.64 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $17.40 | 2025 | Ozempic |
| Vantive US Healthcare LLC | $15.10 | 2025 | Renal - Pd |
| Boston Scientific Corporation | $12.77 | 2021 | |
| Biomerieux INC | $9.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deewan Deewan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.